Professor Emeritus OB/GYN at UCSF, Dr. Golbus Brings Significant Clinical
and Molecular Diagnostic Experience
NOVATO, Calif., April 24 /PRNewswire/ -- Diamics, Inc., a
privately-held company developing products for cancer screening and
diagnostics, has named Mitchell Golbus, MD, to the position of Chief
Medical and Technical Officer. Dr. Golbus is a Professor Emeritus of
Obstetrics and Pediatrics at the University of California, San Francisco.
Dr. Golbus will be responsible for all medical aspects for Diamics
including the medical advisory board and clinical trials and will direct
the final development of the molecular-based cervical screening system for
the company.
"We are delighted to welcome Dr. Golbus to Diamics and are confident
that his extensive background and track record of success in diagnostic
innovation will help the company achieve its goals," said Peter Gombrich,
CEO and Chairman of Diamics. "Mitchell's reputation in the field in
addition to his extensive business experience in the development of
innovative products will be of great value to Diamics as we move ahead with
our worldwide clinical trials. In addition, because of his experience in
genetics, he will drive the next-generation advances in molecular-based
systems being undertaken by the company. We are very fortunate to be able
to attract someone of his caliber as part of the Diamics team."
"I am excited about joining such a strong management team and working
on Diamics' technology that combines molecular markers with cervical
mapping to offer a simple yet sophisticated approach to cervical cancer
screening," said Dr. Golbus. "I am looking forward to leading the medical
developments that will allow the Diamics' technology to be easily adapted
as a point of care test to help expand cervical cancer screening
worldwide."
Dr. Golbus is Board Certified in both Obstetrics/Gynecology and Medical
Genetics. He received his degree in medicine from the University of
Illinois in 1963. He completed his residency, was a research fellow and
became Professor at UCSF in 1981. He has held the position as Professor
Emeritus since 1994. While at UCSF he founded several diagnostic companies
specifically dealing with genetic karyotyping. Between 1994 and 1998 he was
a consultant to Applied Imaging (Santa Clara, CA) on research to develop a
prenatal test using fetal cellular material in the maternal circulation.
From 1999 to present he has participated in medical missions to Guatemala.
He has published over 240 peer-reviewed articles, has written 60 book
chapters and has had over 120 accepted and published abstracts.
Diamics recently received FDA 510(k) clearance for its innovative
CerCol(TM) collector for collection of cervical cytology material and its
transfer for Pap analysis. The Beijing Jingmin Hospital Group recently
awarded the Company a contract to provide the CerCol(TM) collectors and
Diamics' next generation molecular-based automated cervical cancer
screening systems to the hospital group.
About Diamics, Inc.
Diamics, Inc. is a privately owned medical device and diagnostics
company located in the San Francisco Bay Area. The company is committed to
developing, manufacturing, and marketing cost effective, molecular-based
cancer screening and diagnostic systems that will increase long-term cancer
survival rates through early detection. Diamics' management team has an
extensive track record of success in the medical device and diagnostics
industries. The company's mission is twofold: to help medical personnel
worldwide improve the lives of the people they treat and to generate a
return on investment for its shareholders. For more information, please
visit http://www.diamics.com.
| |
SOURCE Diamics, Inc.
 back to top
Related links:
http://www.diamics.com
CONTACT:
Christine Meda, President, COO of Diamics,
Inc., +1-415-883-0414, cmeda@diamics.com; or Jennifer Larson,
+1-415-409-2729, jlarson@labfive.com, for Diamics, Inc.
| |
|
